(NASDAQ: ALDX) Aldeyra Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.87%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.74%.
Aldeyra Therapeutics's revenue in 2025 is $0.On average, 8 Wall Street analysts forecast ALDX's revenue for 2025 to be $1,488,126,190, with the lowest ALDX revenue forecast at $0, and the highest ALDX revenue forecast at $9,191,668,459. On average, 8 Wall Street analysts forecast ALDX's revenue for 2026 to be $2,027,545,613, with the lowest ALDX revenue forecast at $943,352,281, and the highest ALDX revenue forecast at $5,173,697,664.
In 2027, ALDX is forecast to generate $3,059,457,495 in revenue, with the lowest revenue forecast at $2,364,276,653 and the highest revenue forecast at $3,699,709,726.